Neuroendocrinology (DOI:10.1159/000431379)
(Accepted, unedited article not yet assigned to an issue)
© 2015 S. Karger AG, Basel www.karger.com/nen
Advanced Release: May 29, 2015
Received: February 3, 2015 Accepted after revision: May 15, 2015
Long‐term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases Stefano Partelli1^, MD, Marco Inama2, MD, Anja Rinke3, MD, Nehara Begum4, MD, Roberto Valente2, MD, Volker Fendrich5, MD, Domenico Tamburrino2, MD, Tobias Keck3, MD, Martyn E. Caplin6, MD, Detlef Bartsch5* , MD, Christina Thirlwell, MD7, Giuseppe Fusai2*, MD, and Massimo Falconi1*^, MD From the 1Pancreatic Surgery Unit, University Hospital of Ancona, Ancona, Italy 2 Hepato‐pancreato‐biliary and liver transplant surgery, Royal Free Hospital, London, United Kingdom 3 Department of Gastroenterology, University Hospital Marburg, Marburg, Germany 4 Department of Surgery, Hospital Schleswig‐Holstein, Campus Luebeck, Luebeck, Germany 5 Department of Surgery, University Hospital Marburg, Marburg, Germany 6 Centre for Gastroenterology, Royal Free Hospital, London, United Kingdom 7 UCL Cancer Institute and Royal Free Hospital NET Unit, London, United Kingdom * Detlef Bartsch, Giuseppe Fusai and Massimo Falconi share the senior authorship ^ Current affiliation: Pancreatic Surgery Unit, San Raffaele Hospital, Vita‐Salute San Raffaele University, Milan, Italy Corresponding author: Prof. Massimo Falconi Pancreatic Surgery, Unit San Raffaele Scientific Institute‐Salute e Vita University Via Olgettina, 60 20134 Milan, Italy Phone: +39 02.2643.6020 Email:
[email protected] Sources of support: the present study was not funded Conflict of interest: authors have no conflict of interest to declare Running Head: Metastatic Pancreatic Neuroendocrine Tumors Abstract Background: The value of surgical resection in the management of PNET with LM is still
neuroendocrine tumors (PNET) with liver metastases (LM). Methods: Patients with PNET with
Downloaded by: University of Georgia 128.192.114.19 - 6/10/2015 1:59:13 AM
debated. The aim of the study was to evaluate the outcomes of surgery of pancreatic
Neuroendocrinology (DOI:10.1159/000431379)
© 2015 S. Karger AG, Basel
2
synchronous LM between 2000 and 2011 from 4 high‐volume Institutions were included. Patients were divided into 3 groups (curative resection, palliative resection, and no resection). Results: Overall 166 patients were included. Eighteen patients (11%) underwent curative resection, 73 patients (43%) underwent palliative resection, and 75 patients (46%) underwent conservative treatment. The median overall survival (OS) from diagnosis was 73 months. Patients who underwent curative resection had a significantly better median OS from initial diagnosis compared with those who underwent palliative resection and those who were conservatively treated (97 versus 89 versus 36 months, P=0.0001). The median OS from diagnosis in those patients who underwent radical or palliative resection was 97 months with a 5‐year survival rate of 76%. On multivariate analysis, factors associated with OS from diagnosis were the presence of bilobar metastases, tumor grading and curative resection in a first model. On a second model, curative or palliative surgery was an independent predictor of OS. Among 91 patients who underwent surgery, the presence of PNEC‐G3 was the only factor independently associated with a poorer survival after surgery (median OS: 35 months versus 97 months, P25 mm 2nd model Liver metastases distribution Unilobar Bilobar Tumor grading* G1 G2 G3 Treatment No resection Curative/palliative resection Size of largest liver metastases ≤25 mm >25 mm
HR
Overall Survival 95% CI P
Progression Free Survival HR 95% CI P
0.004
1 1.171
0.6891.990
1.026-4.124 3.32217.475
0.042 0.0001
1 1.706 2.416
1.0252.837 1.2874.533
0.040 0.001
1 0.728 0.484
0.301-1.754 0.289-0.811
0.480 0.006
1 0.572 0.675
0.2801.169 0.4370.890
0.135 0.039
1 1.460
0.868-2.458
0.154
1 2.755
1.352-5.614
0.005
1 1.585
0.9652.602
1 1.999 7.228
1.000-3.996 3.17916.436
0.050 0.0001
1 1.549 2.524
0.9872.429 1.4604.431
0.057 0.001
1 0.512
0.312-0.839
0.008
1 0.682
0.4730.983
0.040
1 1.356
0.833-2.205
0.008
0.561
0.069
Downloaded by: University of Georgia 128.192.114.19 - 6/10/2015 1:59:13 AM
*According to WHO classification [26] HR= Hazard Ratio CI=Confidence interval
Neuroendocrinology (DOI:10.1159/000431379)
© 2015 S. Karger AG, Basel
18
Neuroendocrinology (International Journal for Basic and Clinical Studies on Neuroendocrine Relationships) Journal Editor: Millar R.P. (Edinburgh) ISSN: 0028-3835 (Print), eISSN: 1423-0194 (Online)
www.karger.com/NEN Disclaimer: Accepted, unedited article not yet assigned to an issue. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center. © 2015 S. Karger AG, Basel
Downloaded by: University of Georgia 128.192.114.19 - 6/10/2015 1:59:13 AM